PI Industries Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹42,633 Cr
- Book Value
- ₹739.47
- Stock P/E
- 35.5
- Dividend Yield
- 0.53%
- ROE
- 11.2%
- ROCE
- 15.0%
- PEG Ratio
- 3.55
- EV/EBITDA
- 19.9
Fundamentals from Screener.in, as of 6 Aug 2026. Live price via Yahoo Finance.
PI Industries share price today
PI Industries Ltd (NSE: PIIND) had a market capitalisation of ₹42,633 Cr and a recorded price of ₹2,774.60 in Gale’s internal 6 August 2026 snapshot. Its 52-week range was ₹2,537.20 to ₹4,023.80, leaving the share about 31% below the high. The quote box above is live, but the operating and valuation figures in this article remain frozen to that dated research snapshot. That separation prevents a moving market price from being presented beside stale ratios as though both were current.
The investment question is unusually sharp. PI owns a respected custom-synthesis and agrochemical platform, earns a 26% operating margin in the internal data and carries little financial debt. Yet the business has entered a real earnings trough: the snapshot records trailing sales down 16% and profit down 28%, while the company’s audited FY26 presentation reports a 16% revenue decline and a 20% fall in reported profit after tax. A lower share price does not by itself resolve that conflict. Investors need evidence that customer destocking is ending, new molecules can replace mature volumes and the pharma investment can earn acceptable returns.
What PI Industries actually does
PI began as an agricultural-input company but is now best understood as a chemistry and process-development platform. Its custom-synthesis manufacturing business works with global innovators to develop and manufacture complex molecules, historically led by crop-protection products. The domestic business distributes branded crop solutions to Indian farmers. A newer pharma platform is being assembled through research capabilities and acquired businesses.
Those activities have different economics. Custom synthesis can create long customer relationships, technical switching costs and repeat volumes, but it is exposed to the product cycles and inventory decisions of a concentrated group of innovators. Domestic formulations provide brand and distribution reach, though monsoons, crop prices, regulation and channel inventory can make seasons volatile. Pharma expands the addressable market beyond agrochemicals, but it is still small enough that investors should treat it as an option to be proven rather than a finished second engine.
| Business engine | FY26 evidence | What investors should test |
|---|---|---|
| Agchem exports | Revenue declined 19%; volume fell about 14% | Whether customer inventory normalises and new launches offset mature molecules |
| Domestic agri brands | Revenue declined 7%; volume fell 1% | Market share, weather sensitivity and channel inventory quality |
| New export products | 18% of agchem export revenue | Repeat orders and margin after launch costs |
| Pharma | Revenue grew 40%; roughly 6% of export revenue | Scale, customer validation and return on invested capital |
| Research and manufacturing | Five molecules commercialised in FY26 | Conversion of pipeline work into durable commercial volumes |
This portfolio explains both the attraction and the current stress. PI is not a commodity pesticide producer whose fate rests only on spot prices, but neither is it immune from the agricultural cycle. The moat is the ability to solve difficult chemistry, move a molecule from laboratory to commercial scale, meet demanding quality standards and retain a customer through the product’s life. The central risk is that a technically strong platform can still suffer when customers carry too much inventory or when important molecules approach a softer phase of their life cycle.
FY26 was a trough, not a harmless pause
PI’s FY26 investor presentation shows revenue falling from ₹7,977.8 Cr to ₹6,713.7 Cr. EBITDA declined from ₹2,183.3 Cr to ₹1,705.3 Cr, and profit after tax moved from ₹1,660.2 Cr to ₹1,320.8 Cr. Gross margin increased from 53% to 58%, but EBITDA margin fell from 27% to 25%. That combination matters: richer mix and cost actions protected gross economics, while lower utilisation and operating deleverage still reduced profit.
Reported profit also needs an accounting footnote. FY26 included a ₹126 Cr contingent-consideration write-back, partly offset by a ₹22.9 Cr labour-code provision. A one-time write-back is not equivalent to cash earned from selling molecules. The internal snapshot’s steeper 28% trailing profit decline is therefore a useful warning against reading the reported number without normalisation.
| FY26 consolidated measure | FY25 | FY26 | Change / interpretation |
|---|---|---|---|
| Revenue | ₹7,977.8 Cr | ₹6,713.7 Cr | Down 16%; broad demand and inventory pressure |
| Gross margin | 53% | 58% | Up 507 bps; better mix and procurement helped |
| EBITDA | ₹2,183.3 Cr | ₹1,705.3 Cr | Down 22%; lower scale outweighed gross-margin gain |
| EBITDA margin | 27% | 25% | Down 197 bps; evidence of operating deleverage |
| Reported PAT | ₹1,660.2 Cr | ₹1,320.8 Cr | Down 20%; includes a contingent-consideration write-back |
| Agchem export volume | — | — | Down about 14%; the issue was not currency alone |
Calling this a trough is a hypothesis, not a fact. A genuine cyclical trough should be followed by improving order visibility, better plant utilisation and narrowing year-on-year declines. A structural problem would look different: repeated order deferrals, weak commercialisation, price concessions, a shrinking share of customer programmes or capital spending that does not translate into revenue. The stock’s fall from its 52-week high only says the market has lowered expectations; it does not tell us which diagnosis is correct.
Custom synthesis: the moat and its concentration risk
Custom synthesis requires scientific talent, process engineering, safe scale-up, regulatory discipline and dependable delivery. Customers share valuable intellectual property and place a molecule inside a regulated supply chain, so a proven supplier can be difficult to replace. PI’s long relationships and manufacturing record are genuine assets. Five molecule commercialisations in FY26 and an 18% contribution from newer products indicate that the pipeline is producing revenue rather than remaining only a presentation slide.
However, product concentration is intrinsic to this model. A large molecule can contribute attractive volume for years and then slow as customer inventory rises, competing products arrive or the end market weakens. Revenue recognition can also be lumpy around campaign scheduling. Investors should therefore avoid extrapolating either the best year or the worst quarter. The healthier test is whether several newer molecules broaden the revenue base and whether customer advances, receivables and inventory move consistently with commercial demand.
PI’s higher FY26 gross margin is encouraging because it suggests pricing and mix did not collapse. It is not sufficient evidence of recovery because fixed manufacturing, research and people costs must be absorbed by a lower revenue base. The base scenario in this article assumes gradual normalisation rather than a rapid return to the previous peak. The bull case requires new launches, improving volumes and disciplined pharma execution together. The bear case allows the platform to remain profitable while assigning little benefit to a quick rebound.
Domestic agriculture adds brands but also weather
The domestic business launched four products during FY26, yet revenue declined 7% as weather, crop economics, biological-product regulation and channel inventory affected demand. Volume was down only 1%, implying that mix and pricing also shaped the result. This is a reminder that a broad distribution network cannot eliminate farm-level affordability or climatic volatility.
High-quality domestic growth would have three features. First, it would come from farmer adoption and repeat use rather than stocking distributors ahead of the season. Second, working capital would not deteriorate to manufacture reported sales. Third, new products would earn enough margin after promotion to improve the portfolio, not merely replace older brands at lower economics. Management commentary should be checked against receivable days and channel inventory whenever growth returns.
Policy is another variable. Registration timelines, product bans, price sensitivity and changing rules for biological inputs can affect launch schedules. These risks are different from custom synthesis and partly diversify the group, but they also make consolidated forecasting less precise. A valuation premium is deserved only when the portfolio demonstrates resilience across both export and domestic cycles.
Pharma is promising, but capital still has to prove itself
Pharma revenue grew 40% in FY26 and represented about 6% of export revenue. The strategic logic is clear: PI can reuse chemistry, process development and regulated-manufacturing capabilities in a larger market while reducing dependence on crop-protection cycles. The harder question is economic. Early growth from a small base can look impressive before fixed costs, acquisition consideration and additional capital are fully reflected.
Investors should monitor programme wins, commercial launches, customer concentration, regulatory observations and segment cash generation. Acquired platforms need to create value above their cost, not only add reported revenue. If pharma scales with acceptable margins and limited incremental working capital, it can change PI’s earnings duration. If repeated investment is required while agchem cash flow is weak, it can delay recovery and depress return on capital.
| Evidence for the next phase | Constructive signal | Adverse signal |
|---|---|---|
| Export order flow | Sequential volume stabilisation across more than one molecule | Repeated customer deferrals or further destocking |
| New molecule mix | Rising revenue with repeat campaigns and steady margin | Launch count rises but commercial revenue remains small |
| Pharma platform | Customer validation, scale and improving capital productivity | Acquisition-led growth without cash returns |
| Domestic franchise | Farmer-led demand and clean channel inventory | Sales supported by extended credit or channel loading |
| Plant utilisation | Better absorption without sacrificing safety or quality | Idle capacity and persistent operating deleverage |
Growth, margins and capital efficiency
The internal snapshot shows five-year sales growth of 8% and five-year profit growth of 10%. Over three years, sales grew only 1% annually and profit declined 1%, revealing how sharply recent weakness has interrupted the longer record. ROCE of 15% and ROE of 11.2% are respectable but below what a premium specialty-chemistry valuation should ideally deliver. Five-year average ROE was 16%, another sign that the current return profile is depressed.
| Internal operating evidence | 6 Aug 2026 snapshot | Reading |
|---|---|---|
| Sales CAGR, 5 years | 8% | Full-cycle growth has been moderate, not spectacular |
| Profit CAGR, 5 years | 10% | Some historical operating leverage |
| Sales CAGR, 3 years | 1% | Recent cycle has largely erased momentum |
| Profit CAGR, 3 years | -1% | Earnings have not compounded recently |
| Operating margin | 26% | Strong chemistry economics despite the downturn |
| ROCE | 15% | Adequate, but recovery capex must lift this return |
| ROE / five-year ROE | 11.2% / 16% | Current shareholder return is below its own history |
The margin tells us PI still owns useful capabilities. The return ratios tell us those capabilities are not currently being monetised at the old level. Recovery quality should be measured through incremental ROCE: how much additional operating profit arrives for each rupee already invested. Simply restoring revenue by offering easier terms or spending heavily on unproven capacity would not deserve the same multiple as a volume-led recovery using existing assets.
Balance sheet, ownership and cash conversion
Debt to equity was only 0.03 in the internal snapshot, and promoter holding was 46.09% with no pledged shares. That balance-sheet position is valuable during a trough because the company can maintain research and selective capital spending without financial distress. It also removes a common excuse: future returns should be judged on operating execution rather than leverage-driven ROE.
| Financial resilience check | Snapshot | Why it matters |
|---|---|---|
| Debt/equity | 0.03 | Low balance-sheet risk provides time for recovery |
| Promoter holding | 46.09% | Meaningful alignment, still requiring governance review |
| Promoter pledge | 0% | No pledge overhang in the dated snapshot |
| Book value per share | ₹739.47 | Useful context for capital employed, not a floor to price |
| Dividend yield | 0.53% | Most expected return depends on earnings, not income |
Low debt does not guarantee good capital allocation. The next questions are where growth capital goes, whether pharma acquisitions achieve their promised returns and whether inventory or receivables absorb cash during a rebound. A recovery that generates operating cash and lifts utilisation is stronger than one that consumes working capital. Investors should compare cash from operations with reported profit across several periods, especially while customer inventories normalise.
The numbers
| Metric | Internal 6 Aug 2026 snapshot |
|---|---|
| Market capitalisation | ₹42,633 Cr |
| Snapshot price | ₹2,774.60 |
| P/E · price/book | 35.5× · 3.80× |
| PEG · EV/EBITDA | 3.55 · 19.9× |
| ROE · ROCE | 11.2% · 15.0% |
| Operating margin | 26% |
| Debt/equity | 0.03 |
| EPS (TTM) | ₹79.15 |
| Book value per share | ₹739.47 |
| 52-week range | ₹2,537.20 – ₹4,023.80 |
Valuation: recovery is already part of the price
The snapshot P/E of 35.5 times and EV/EBITDA of 19.9 times are below some historical specialty-chemical peaks, but they are not automatically cheap against falling trailing earnings and an 11.2% ROE. Price/book of 3.8 times requires the capital base to earn materially more over time. PEG of 3.55 also warns that the valuation is high relative to the recorded five-year profit growth rate, although PEG is unreliable when earnings sit near a cyclical trough.
This target framework starts with the exact internal TTM EPS of ₹79.15. Each year compounds that same base using one stated earnings-growth rate, then applies the scenario’s exit P/E and rounds the displayed price to the nearest ₹5. The bear case assumes only modest earnings progress and a lower multiple. The base case assumes a measured recovery without returning to peak optimism. The bull case requires successful new molecules and pharma scaling while still using a finite multiple.
| Scenario | EPS growth assumption | Exit P/E | Business interpretation |
|---|---|---|---|
| Bear | 3% | 24× | Trough lasts longer, volumes stay soft and valuation compresses |
| Base | 10% | 32× | Agchem demand normalises gradually and margins rebuild |
| Bull | 16% | 40× | New molecules scale, pharma contributes and returns improve |
PI Industries share price target 2026 to 2030
The annual outcomes below are sensitivities, not predictions. The formula starts at the 6 August 2026 TTM EPS, applies 147/365 of the annual growth rate for the 2026 year-end row, adds one full year for every later row, and then applies the stated exit P/E. It deliberately allows earnings and valuation to move together because disappointments often reduce both, while clean execution can improve both.
Scenario warning: customer ordering, molecule life cycles, regulation, currency, acquisitions and market multiples can all fall outside these assumptions. The table is a decision aid, not a guaranteed price path or personalised recommendation.
What would change the thesis
The recovery case would strengthen if export volumes stabilised across multiple molecules, FY27 commercialisations generated repeat campaigns, EBITDA margin recovered with utilisation and pharma growth began to improve group-level capital returns. Clean operating cash conversion would confirm that the improvement was not merely inventory moving from PI’s balance sheet into the channel.
It would weaken if the agchem decline persisted beyond normal customer destocking, mature products lost relevance faster than replacements scaled, pharma required repeated funding without commercial returns, or working capital rose despite weak growth. A regulatory or quality event would also require rebuilding the model rather than making a small adjustment to a spreadsheet.
| Quarterly review item | Why it matters | Evidence required |
|---|---|---|
| Agchem export volume | Distinguishes recovery from price or currency effects | Volume growth and customer-order commentary |
| New products’ revenue share | Tests pipeline conversion | Repeat commercial sales, not launch announcements alone |
| EBITDA margin | Measures utilisation and mix | Sequential improvement supported by gross profit and costs |
| Pharma revenue and losses | Tests the diversification option | Scale, customer wins and segment economics |
| Operating cash flow | Confirms earnings quality | Cash conversion after inventory and receivables |
| ROCE | Connects growth to shareholder value | Rising operating profit relative to capital employed |
Should you buy PI Industries at the current price?
PI remains a high-capability chemistry business with a strong balance sheet, but the dated valuation still asks investors to underwrite a meaningful recovery. The sensible decision is not based on the distance from the 52-week high. It depends on whether new-molecule revenue, order flow and capital returns are improving fast enough to support the multiple.
Existing shareholders can track evidence rather than react to every quote. New investors should insist on a margin of safety because earnings and multiple compression can occur together. The signed-in panel contains Gale’s current classification, and paid members can view the model’s accumulation band; neither should substitute for personal risk capacity, diversification or advice from a registered professional.
FAQ
What is the PI Industries share price target for 2030?
Gale presents bear, base and bull outcomes for every year from 2026 through 2030 in the signed-in table. They are derived from the disclosed EPS-growth and P/E assumptions rather than a single assured forecast.
Why did PI Industries’ FY26 revenue decline?
The company reported pressure from global customer destocking and lower agchem export volumes, while domestic demand faced weather, crop-price, regulatory and channel-inventory factors. Investors should watch whether volumes stabilise across several quarters.
Is PI Industries only an agrochemical company?
Agrochem custom synthesis and domestic crop solutions remain central, but PI is building a pharma platform using research, process-development and manufacturing capabilities. Pharma is growing from a small base and should still be evaluated as an emerging business.
What is PI Industries’ strongest competitive advantage?
Its advantage is the combination of chemistry research, process scale-up, regulated manufacturing and long customer relationships. The moat is validated when new molecules become repeat commercial programmes with attractive cash returns.
What is the biggest risk in the target model?
The largest risk is treating a cyclical trough as automatically temporary. A slower molecule replacement cycle, sustained destocking or weak pharma returns could reduce earnings growth and the valuation multiple at the same time.
When are PI Industries’ next results?
Check Gale’s results calendar and confirm the announced date through PI Industries’ exchange filing. Dates can change, so an estimate should not be treated as the official schedule.
Related research
- Sharda Cropchem share price target
- Vinati Organics share price target
- Navin Fluorine share price target
Sources and methodology
- PI Industries FY26 investor presentation, including audited FY26 operating data, segment commentary and exceptional items.
- PI Industries annual reports and FY26 integrated annual report.
- Screener.in consolidated financials, captured in Gale’s approved internal research snapshot on 6 August 2026.
Live market data is supplied separately and is indicative. Financial figures are labelled by period so the audited FY26 results are not confused with Gale’s later trailing-twelve-month snapshot.
This article is research and education, not personalised investment advice. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.